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Identification of hepta-histidine as 
a candidate drug for Huntington’s 
disease by in silico-in vitro- in vivo-
integrated screens of chemical 
libraries
Tomomi Imamura1,*, Kyota Fujita1,*, Kazuhiko Tagawa1,*, Teikichi Ikura2,*, Xigui Chen1, 
Hidenori Homma1, Takuya Tamura1, Ying Mao1, Juliana Bosso Taniguchi1, Kazumi Motoki1, 
Makoto Nakabayashi2, Nobutoshi Ito2, Kazunori Yamada3, Kentaro Tomii4, Hideyuki Okano5, 
Julia Kaye6, Steven Finkbeiner6 & Hitoshi Okazawa1,7
We identified drug seeds for treating Huntington’s disease (HD) by combining in vitro single molecule 
fluorescence spectroscopy, in silico molecular docking simulations, and in vivo fly and mouse HD models 
to screen for inhibitors of abnormal interactions between mutant Htt and physiological Ku70, an 
essential DNA damage repair protein in neurons whose function is known to be impaired by mutant Htt. 
From 19,468 and 3,010,321 chemicals in actual and virtual libraries, fifty-six chemicals were selected 
from combined in vitro-in silico screens; six of these were further confirmed to have an in vivo effect 
on lifespan in a fly HD model, and two chemicals exerted an in vivo effect on the lifespan, body weight 
and motor function in a mouse HD model. Two oligopeptides, hepta-histidine (7H) and Angiotensin III, 
rescued the morphological abnormalities of primary neurons differentiated from iPS cells of human 
HD patients. For these selected drug seeds, we proposed a possible common structure. Unexpectedly, 
the selected chemicals enhanced rather than inhibited Htt aggregation, as indicated by dynamic light 
scattering analysis. Taken together, these integrated screens revealed a new pathway for the molecular 
targeted therapy of HD.
Huntington’s disease (HD) is an autosomal dominant disease linked to a CAG repeat expansion in the first exon of 
the huntingtin gene located in chromosome 4 at position 16.3. A great deal of knowledge has accumulated regarding 
the pathological mechanisms and physiological functions of the huntingtin (Htt) gene, RNA and protein. 
The hairpin and other higher structures formed by the CAG repeat sequence of the Htt gene DNA1–4 might 
affect transcription and DNA repair and subsequently induce instability of the triplet repeat5,6 and the RNA 
toxicity7 associated with ataxin-38 or non-coding triplet repeat diseases, such as myotonic dystrophy9. Moreover, 
the effect of ataxin-810 might be mediated by CAG siRNA/miRNA7 or by sequestration of RNA splicing pro-
teins, such as muscleblind-like 111–13, numerous proteins that interact with Htt, such as HAP114, HIP115, p5316, 
1Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, 
Bunkyo-ku, Tokyo 113-8510, Japan. 2Department of Structural Biology, Medical Research Institute, Tokyo Medical 
and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. 3Graduate School of Information 
Sciences, Tohoku University, 6-3-09, Aramaki-Aza-Aoba, Aoba-ku, Sendai 980-8579, Japan. 4Cellular System 
Analysis Team, Computational Biology Research Center, National Institute of Advanced Industrial Science and 
Technology, 2-4-7, Aomi, Koto-ku, Tokyo 135-0064, Japan. 5Keio University School of Medicine, 35 Shinanomachi, 
Shinjuku-ku, Tokyo 112-0012, Japan. 6Taube/Koret Center for Neurodegenerative Disease, Gladstone Institute of 
Neurological Disease, and the Departments of Neurology and Physiology, University of California San Francisco, 
San Francisco CA 94158, USA. 7Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 
Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. *These authors contributed equally to this work. Correspondence and 
requests for materials should be addressed to H.O. (email: okazawa-tky@umin.ac.jp)
Received: 01 June 2016
Accepted: 02 September 2016
Published: 22 September 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:33861 | DOI: 10.1038/srep33861
PACSIN117 and other factors. In addition, PQBP1, PQBP3, PQBP518–20 and TERA/p97/VCP18,21 interact with 
polyglutamine (polyQ) disease proteins via polyQ tract sequences, including Htt22.
However, a combined study of multiple pathological molecules and/or mechanisms has not been performed 
systematically, and the relative significance of any single mediator molecule among a number of players has been 
difficult to evaluate. Furthermore, the relative contribution of the molecule to the total pathology remains unclear. 
Thus, the most essential focus for therapeutic development has not been determined, and no definitive effective 
therapy against HD has been identified thus far.
The use of the same mouse model enables a comparison of the multiple results from different laboratories on 
the same platform. For instance, the R6/2 transgenic mouse expressing Htt exon1-Q120 ± 523 has a long history 
of use in HD research, although whether overexpression of a partial fragment of the mutant protein completely 
reflects human pathology has been debated. However, it is generally accepted that some features of the R6/2 
mouse pathology mimic human HD. We used this model to investigate the pathological function of Ku7024; 
protein-protein interaction screenings identified this protein as molecule that directly interacts with Htt25. 
Furthermore, transgenic overexpression of Ku70 resulted in one of the longest lifespan extensions in R6/2 mice24.
In the same study, we found that mutant Htt interacts with Ku70 and impairs its function in non-homologous 
end-joining (NHEJ), a type of DNA double-strand break repair (DDBR) that functions in non-dividing cells 
such as differentiated neurons24. Mutant Htt expression induces DNA damage 3–4 days prior to the cell death 
of primary cortical neurons24 and activates DNA damage signaling molecules, such as Chk1/226; these changes 
support the hypothesis that impairment of Ku70 by a mutant protein is an upstream event of neurodegeneration.
Given that previous results have suggested the importance of Ku70 relative to various mediator molecules, we 
screened chemicals that could inhibit the interaction between Ku70 and mutant Htt. We combined an in vitro 
screen, in silico screen, Drosophila screen and mouse screen, and we then validated the effect with human iPS cells 
obtained from HD patients. Consequently, we obtained 6 chemicals that were effective in a Drosophila model. We 
tested 3 of these chemicals and confirmed the therapeutic effect of 2 chemicals in ameliorating the body weight 
loss and lifespan shortening of R6/2 mice. One chemical was difficult to synthesize on a large scale.
Unexpectedly, hepta-histidine (7H) was the most effective among the chemicals identified from non-biased 
screens of chemical libraries in this study. We included 7H not only because it was proposed as a candidate on 
the basis of the in silico screening using Discovery Studio but also because it is a polar oligopeptide that might 
interact with a polyQ tract of Htt via multiple hydrogen bonds of the polar zipper structure, as proposed by 
the Nobel Prize Laureate Max Perutz27. Histidine has a positively charged imidazole group, a positively charged 
amino group and a negatively changed carboxyl group, and amino acids possessing such polar groups generally 
contribute to the formation and maintenance of higher protein structures.
L-histidine is a semi-essential amino acid specifically required by young people to grow and repair tissues, and 
it plays important roles in immunity, gastric secretion, and sexual function. It is metabolized into a neurotrans-
mitter histamine and is necessary for myelin sheath development. The FDA permits the addition of L-histidine 
to food. Regarding its toxicity, the LD50 of L-histidine is greater than 15,000 mg/kg for oral intake, greater than 
8,000 mg/kg for peritoneal injection, and greater than 2,000 mg/kg for intravenous injection in a rat or mouse 
(pubchem.ncbi.nlm.nih.gov/compound/L-histidine), which is far lower than the effective dose for HD models 
determined in this study. Therefore, 7H might be a drug seed that can be used safely for HD.
Results
First wet screening using single molecule fluorescence spectroscopy. We employed both wet and 
dry screens (MF20 and Discovery Studio, respectively) for the initial step, performed a secondary screening with 
single molecule fluorescence spectroscopy, and examined the phenotypic effects in Drosophila and mouse models 
as the third and fourth screens (Fig. 1).
For the first wet screening of our in-house chemical library (19,468 chemicals or peptides) at the TMDU 
Chemical Biology Screening Center (http://mechpc5.tmd.ac.jp:3000/cbdb), we employed single molecule flu-
orescence spectroscopy (MF20, Olympus) and examined the effect of chemicals or peptides from the library 
on the interaction between normal Ku70 protein (Ku70-HisTag expressed in E. coli by the pET28 vector) and 
mutant Htt protein (GST-HttExon1-110Q). This apparatus detects the interaction of a fluorescent molecule 
and a non-fluorescent molecule in 1 × 10−15 L in several seconds and is available for high-throughput screening 
(Supplementary Figure 1a).
Prior to the start of the screening, we tested the efficiency of two methods, fluorescence correlation spectros-
copy (FCS) and fluorescence intensity distribution analysis-polarization (FIDA-PO). The former was used to eval-
uate the diffusion time and the latter was used to estimate the fluorescence polarization of a fluorescent molecule 
(Supplementary Figure 1b). In both cases, when a fluorescent protein binds to another non-fluorescent protein, 
the diffusion time and the polarization both increase (Supplementary Figure 1b). Indeed, we fluorescently labe-
led and resolved the Ku70-HisTag protein at 5 nM in a volume of 40 μ l. Next, different concentrations of anti-Ku 
antibody, as a positive control, or GST-HttExon1-110Q were added to the solution. Compared to their respective 
negative controls (i.e., non-specific mouse IgG and GST protein), FIDA-PO but not FCS detected a change due to 
the positive control and a change caused by GST-HttExon1-110Q at 500 nM (Supplementary Figure 1c). Thus, we 
selected FIDA-PO in this condition (5 nM Ku70-HisTag and 500 nM GST-HttExon1-110Q) for further screening.
Next, we performed the first screening using our in-house chemical library (19,468 chemicals or peptides). 
Fluorescence polarization was recorded 10 times/well in two wells using a single chemical from the library 
(Supplementary Figure 1d). In the absence of GST-HttExon1-110Q in the solution, the fluorescence polarization 
score was approximately 120, which indicates the non-binding state of Ku70. In the presence of GST-HttExon1-
110Q, the fluorescence polarization score increased to nearly 140. With the addition of a molecule from the 
chemical library, the score was decreased, increased or remained unchanged. A decreased score reflected the dis-
sociation of Ku70-HisTag from GST-HttExon1-110Q by the molecule. An increased score could not be explained 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:33861 | DOI: 10.1038/srep33861
well, but it might be due to either the polymer or aggregate formation of Ku70-HisTag in the presence of the 
chemical or the high polarization of the chemical itself. An unchanged score meant no effect of the molecule on 
interaction between Ku70-HisTag and GST-HttExon1-110Q.
Figure 1. Multidisciplinary screens for drug seeds of Huntington’s disease. The screening strategy to 
obtain drug seeds for Huntington’s disease is shown schematically. TMDU chemical library, virtual library 
and polyamines are objectives of the screens. The first screens are based on the ability of a chemical to prevent 
the interaction between Ku70 and mutant Htt, that is actually confirmed by single molecular fluorescence 
spectroscopy (MF20) or expected from virtual docking simulation by Discovery Studio. The number of 
chemicals selected for each screen and the related Supplementary Tables are also shown. MF20 is used for 2nd 
screen. Drosophila and mouse model (R6/2 mice) are used for 3rd and 4th screens. Selected chemicals are listed 
in the indicated Figures and Supplementary Figures.
www.nature.com/scientificreports/
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It was possible for intermolecular binding to occur with Ku70-HisTag. However, our data indicated that 
the intermolecular binding of Ku70-HisTag was not as strong as the interaction between Ku70-HisTag and 
GST-HttExon1-110Q (Supplementary Figure 1d).
We used 384 wells in a glass-bottom plate for screening; 2 wells were used for the same chemical. Internal 
positive and negative controls were added at four positions, including the wells in the first and last positions 
(Supplementary Figure 1d). Eventually, for the second screening, we selected 177 chemicals whose score 
decreased to values that were between + 5% and − 5% of the mean value (Supplementary Table 1).
The Ku70-HisTag expressed and purified from E. coli was confirmed to be in a native functional state by 
pull-down assay with nuclear extract of HEK293 cells showing that Ku70-HisTag possessed the ability to inter-
act with endogenous Ku80 (Supplementary Figure 1e). In this experiment, Ku80 was not pulled down with 
Tau-HisTag as a negative control (Supplementary Figure 1e).
First dry screening using Discovery Studio. Next, we performed a virtual screening of chemicals using 
the docking simulation software Discovery Studio. We retrieved the structure of Ku70 (ID: PD0220) from the 
Protein Data Bank (PDB) (http://www.rcsb.org/pdb/explore/explore.do?structureid= 1JEY) and screened 
3,010,121 chemicals in Chemical Available Purchase (CAP) 2006 (Dassault Systems BIOVIA Cooperation, San 
Diego) using LibDock.
First, we performed a docking simulation of various lengths of polyQ to various segments of Ku70 (Fig. 2a, 
site 1–26) and revealed binding of the polyQ peptide to a dip in the N-terminal region (site 4), which had been 
previously shown to interact with mutant HttExon124. A 3D image of the docking of 6Q to the dip was generated 
Figure 2. Docking simulation of poly(amino acids) to Ku70. (a) Probabilities of interaction between 
polyglutamine peptides and 26 potential surfaces of Ku70 are shown as LibDock scores expected by Discovery 
Studio. (b) Image showing the simulation of the interaction of hexa-glutamine (6Q) at site 4 of Ku70 
expected by Discovery Studio. (c) LibDock scores (scores for expected binding affinity) of various lengths of 
polyglutamine peptides in a binding simulation with site 4. (d) The 20 polypeptides with the highest LibDock 
scores for binding to site 4. 7H had a higher score than did polyglutamine of various lengths (polyQs).  
(e) LibDock scores of various lengths of polyhistidine peptides for simulations of binding at site 4.
www.nature.com/scientificreports/
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using Discovery Studio (Fig. 2b). Interestingly, 6Q (Gln-Gln-Gln-Gln-Gln-Gln) bound to site 4 with the highest 
affinity, and a shorter polyQ bound with a lower affinity (Fig. 2c). Longer polyQs (length of at least 7) were not 
expected to bind to site 4, which might be due to the limitation of the algorithm in the software.
Thus, site 4 was considered the most plausible binding site for Htt, and we screened 3,010,121 chemicals for an 
interaction with this site. We ranked the chemicals from highest to lowest based on the docking score (LibDock 
score) and selected the top 20 chemicals that were commercially available for the second screening with MF20.
Interestingly, the software predicted that 7H (His-His-His-His-His-His-His) could bind to Ku70 at site 4 with 
higher affinity than 6Q (Fig. 2d) when we added various lengths of all types of polyamines (lengths of 1–10 a.a.) to 
the in silico screening. Of the various lengths of poly-His, 7H was predicted to interact with Ku70 with the highest 
affinity (Fig. 2e). Thus, we included 6Q and 7H for the second screening.
Second screening using single molecule fluorescence spectroscopy. In total, 177 chemicals from 
the first screening with MF20, 20 chemicals from the docking simulation by Discovery Studio, and 2 polyamines 
(6Q, 7H) were examined in the second screening with MF20 at multiple concentrations (Supplementary Figures 
2, 3). The second biochemical screening confirmed that 46, 8 and 2 molecules, respectively, inhibit the interaction 
between mutant Htt and Ku70 (Fig. 1, Supplementary Table 3).
In this process, we unexpectedly observed that the positive ratios in the second screening were higher for the 
chemicals initially screened by Discovery Studio and for the assumption-based polyamines than the positive ratio 
from the first screening of the chemical library by MF20. These chemicals were subsequently examined in the 
third and fourth screenings using animal models.
Third phenotypic screening using an HD fly model. Because it was impossible to synthesize three of 
the 59 chemicals at a large scale, which was essential for animal models, we examined 56 chemicals in the third 
biological screening using an HD fly model that had been previously developed in our laboratory28,29. The fly 
model expresses the Htt protein in motor neurons under the control of OK6 motoneuron-specific driver, and 
lifespan can be used as a phenotypic marker in chemical or genetic screening28,29.
For instance, we synthesized 7Q and 12Q in addition to 6Q for references. The amount of 7Q recovered from 
the synthesizer was sufficient for the Drosophila screen, whereas we were unsuccessful at synthesizing a sufficient 
amount for the mouse model. The synthesis of 12Q was completely unsuccessful in terms of producing the nec-
essary quantity for a Drosophila model. The tendency of 7Q and 12Q to aggregate at a high concentration during 
the synthesis may account for the failures observed in the chemical synthesis. However, 7H was successfully 
synthesized.
After overcoming such technical issues, we examined 56 chemicals for the third screening and mixed these 
chemicals with food at 500 μ M (Supplementary Figure 4). The third screening revealed that 3 chemicals (7H, 
#4028, and K1127) extended the lifespan, as indicated by a log-rank test at p < 0.01, and an additional 3 chemicals 
(7Q, L5387, FKL01282) exerted an effect with p < 0.05 (Fig. 3a,b). Although the lifespan extensions were not 
large, the effects were reproducible.
Fourth phenotypic screening using Htt-exon1-transgenic mouse model. Thus, we proceeded to 
the fourth screening with R6/2 transgenic mice expressing human mutant Htt exon 1, a well-known mouse model 
with the earliest onset, shortest lifespan, and most severe symptoms relative to those in various HD mouse mod-
els. Despite the debate about whether overexpression of Htt exon 1 might produce some artifacts in the pathology 
or symptoms of HD, compared to other mutant Htt-KI, -YAC-Tg or -BAC-Tg mice, R6/2 is clearly the most 
efficient model for screening multiple chemicals in the shortest duration30.
In the fourth screening with mice, we injected these candidate chemicals intraperitoneally at 50 μ g/g body 
weight. We selected this concentration because LH-RH is used at 2 mg/kg for rat without showing the toxicity 
according to information from Mitsubishi Tanabe Pharma Co., Ltd. (https://medical.mt-pharma.co.jp/di/file/
if/f_lhr.pdf). Angiotensin II is used at 1mg/kg/day31 and Angiotensin was used at 1–30 mg/kg/day32 for peritoneal 
injection. Considering with the concentration, we increased the amount at one order, confirmed that the dose did 
not induce acute toxicity, and employed 50 mg/kg (= 50 ug/g) for the experiment.
With regard to body weight changes, R6/2 mice showed a decline at approximately 9 weeks of age (Fig. 3c). 
This decline continued until death but it was reduced by Angiotensin III (#4028, RVYIHPF) and 7H (p < 0.01 
or p < 0.05 at each weak of age). Motor function, as evaluated using a rotarod test, was also improved by 7H, but 
was not obviously improved by Angiotensin III (Fig. 3d). Angiotensin III and 7H also prolonged the lifespan in 
the most severe HD model, R6/2 mice (p < 0.05). The effect of LH-RH 4–10 peptide (L5387) was not confirmed 
in the three tests (Fig. 3e,f). Although we observed that the lifespan of the HD fly model was prolonged by 7Q 
(Fig. 3a,b), due to the aggregation tendency of 7Q during synthesis, we could not obtain a sufficient amount of 7Q 
for application in the fourth screening using the HD mouse model.
Consistent with the recovery of R6/2 mice, we found a rescue effect of Angiotensin III, LH-RH 4–10 peptide 
and 7H on the DNA damage of the striatal neurons of R6/2 mice using immunohistochemistry with anti-γ H2AX 
and anti-53BP1 antibodies (Supplementary Figure 5a,b). However, none of the three chemicals decreased the 
frequency of inclusion bodies of mutant Htt in the striatum of R6/2 mice when we stained the striatum with 
anti-Htt antibody (EM48) (Supplementary Figure 5c). Western blot analyses using anti-γ H2AX, anti-53BP1 and 
anti-Htt antibodies also supported both the amelioration of DNA damage by 7H, #4028 (Angiotensin III) and 
L5387 (LH-RH 4–10 peptide fragment) and the insensitivity of the mutant Htt aggregation to these chemicals in 
the striatum of R6/2 mice (Supplementary Figure 5d). Ubiquitination of abnormal proteins was also not affected 
by these chemicals (Supplementary Figure 5e). Taken together, these results support the hypothesis that the three 
chemicals restored the phenotypes of the HD fly and mouse models by inhibiting the interaction between the 
disease protein and the target physiological molecule but not by suppressing aggregation, as we expected at the 
www.nature.com/scientificreports/
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Figure 3. Third and fourth screenings with Drosophila and mouse HD models. (a) Six candidate chemicals 
were selected in the third screening of the effect on the lifespan of the Drosophila HD model (Gal4-UAS model 
overexpressing human mutant Htt Exon1-103Q in motor neurons by OK6 driver49). The chemicals were fed 
in corn meal medium at a final concentration of 500 μ M. For the control medium, only solvent was added. 
Twenty virgin female flies were maintained per vial and the number of flies was counted every 2–3 days when 
the meal was replaced with a new one. Log-rank test was used for statistics. (b) Information about the selected 
low molecular weight (LMW) molecules. (c) The fourth screening was performed with background (WT) and 
R6/2 mice fed with the candidate chemicals from the third screening. Chronological changes of body weight are 
shown as mean + /− S.E. *p < 0.05 and **p < 0.01 in Student’s t-test. #p < 0.05 ##p < 0.01 in Tukey’s HSD test.  
(d) Motor function of background (WT) and R6/2 mice fed with the candidate chemicals was analyzed by 
Rotarod test. Mean + /− S.E. are shown in graph. (e) Lifespan of background (WT) and R6/2 mice fed with the 
candidate chemicals. The results of the log-rank test are shown in the lower table. (f) The upper list indicates 
number and gender of mice used for each chemical and control (PBS) in Fig. 2c–e. The lower lists indicate the 
power of statistics at the time-points of each analysis where we judged statistically different. (g) The effect of 
7H on the motor function of mutant Htt-KI mice was analyzed by Rotarod test at 55 weeks of age. The three 
peptides were peritoneally injected for 1 week before the analysis. Rotarod stay times on day 1–3 were compared 
among background mice (+ /+ ), back ground mice injected with 7H (+ /+ + 7H), heterozygous mutant Htt 
knock-in mice (KI/+ ), and mutant Htt heterozygous knock-in mice injected with 7H (KI/+ + 7H). Tukey’s 
HSD test was used for statistics.
www.nature.com/scientificreports/
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beginning of this screening study. However, since we employed only a single dose for mouse experiment, we need 
to select appropriate doses of these peptides in the future.
K1127 (Kemptide acetate salt) was not employed for the fourth screening because a computer search sug-
gested a possible similarity between Kemptide acetate salt and glatiramer acetate (Copaxone), which had been 
tested in an HD mouse model (N171-82Q transgenic mice) and has been previously reported to ameliorate 
the metabolic activity and parameters of motor function, including jumping counts and stereotypic counts33. 
However, a detailed search ruled out a direct relationship between Kemptide acetate salt and these results. Thus, 
Kemptide acetate salt may be the next target molecule for evaluation.
Validation of phenotypic recovery with Htt-KI mice. Regarding the small size effects of Angiotensin 
III, LH-RH 4–10 peptide fragment and 7H on phenotypes of R6/2 mice, we suspected the small effect could be 
due to too severe phenotypes of R6/2 mice and asked whether the effect might become more visible in the other 
HD model expressing full-length Htt at a physiological level. Therefore we tested the effect of 7H on the motor 
function of mutant Htt-KI mice (HdhQ111 mice)34 at the age of 55 weeks around the onset (Fig. 3g). We found the 
definitely positive therapeutic effect of 7H on motor function of Htt-KI mice. However also in this case the extent 
of recovery was small because the difference of motor function between Htt-KI and the control sibling mice was 
not large at this timepoint. Further investigations with more aged Htt-KI mice are planned and will be reported 
elsewhere.
Common molecular structure of candidate chemicals. We attempted to identify the common molec-
ular structure of the selected chemicals. By merging the six chemicals, we determined a common structure 
(Fig. 4a). F1 functions as a donor/acceptor in the hydrogen bond, and F2-4 function as acceptors in the hydrogen 
bond. The structure consists of four hydrogen bond acceptor/donor sites, and it is considered essential for can-
didate chemicals. Interestingly, 6Q and 7H share a similar structure. This result suggested bi-directional binding 
of 7H and other candidate chemicals to Ku70 and polyQ sequences. Discovery Studio predicted that the binding 
affinity (LibDock score) of 7H to the dip of Ku70 would be higher than that of 6Q (Fig. 2d). The incorporation of 
7H at the dip in N-terminal region of Ku70 was also visualized using Discovery Studio (Fig. 4b).
On the other hand, amino acid compositions of 7H, AngIII, and LH-RH 4–10 peptide fragment were very dif-
ferent though they showed similar biological functions. To explain the discrepancy, we assumed that they might 
take similar conformations in the binding pocket of the target protein. To test the hypothesis, we investigated 
their secondary structure under the hydrophobic condition to know conformations of the 3 peptides in the bound 
states, which mimicked the binding pocket because it had higher hydrophobicity than aqueous solution.
We measured the far-UV circular dichroism (CD) spectra of the peptides at 25 °C in PBS containing 0, 10 
or 20% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), which induces a typical hydrophobic environment, by using 
Jasco J-720 spectropolarimeter (Fig. 4c). At 0% HFIP, the CD spectra of the 3 peptides overall showed a common 
feature; there was a positive band around 220 nm, and according as the wavelength decreased, the ellipticity 
decreased to large negative value (Fig. 4c). This feature suggests the random coil conformation, implying that all 
the 3 different peptides commonly take random coil conformation before binding to the protein.
When the concentration of HFIP was increased, the ellipticity of the 3 peptides commonly changed from neg-
ative value to positive one around 200 nm, suggesting that they took the turn-like conformation. Furthermore, a 
negative band, which usually suggests helical conformation, was observed around 220 nm in the CD spectra of 
AngIII (Fig. 4c). In this case, however, the negative value suggested a couple of turns rather than a helical confor-
mation but just, because AngIII is composed of only 7 amino acid residues. Together, the conformations of the 3 
peptides were suggested to take turn-like conformations in the binding pocket under the hydrophobic condition.
Consistently, we obtained the similar results from in silico screening. As shown in Fig. 4b the conformation of 
7H was turn-like in the binding pocket of Ku70 and the conformations of AngIII and LH-RH 4–10 peptides were 
basically similar (data not shown). These results form our wet and dry experiments supported our hypothesis that 
the three peptides take the similar structure in the binding pocket of the target protein.
We also tested whether 7H could inhibit the physical interaction between mutant Htt and Ku70 in vivo, by 
co-immunoprecipitation assay using the cortex tissues of R6/2 mice treated with 7H (Fig. 4d). The results indi-
cated that 7H obviously inhibited interaction between mutant Htt and Ku70 in vivo (Fig. 4d).
Taken together, these results suggested a role of 7H as a competitive antagonist of polyQ in the interaction 
with Ku70. Presumably, 7H competitively binds to the dip of Ku70 with polyQ protein and prevents the interac-
tion between Ku70 and mutant Htt.
Effect of candidate chemicals on Htt aggregation. Furthermore, candidate chemicals might inter-
act with polyQ sequences. We investigated the effect of candidate chemicals on Htt aggregation using in vitro 
and in vivo methods. Dynamic light scattering (DLS), a physics technique for measuring molecular size and the 
corresponding molecular weight in solution35, was employed to analyze the effect of candidate chemicals on the 
dynamic process of GST-HttExon1-110Q aggregation in vitro. This technique successfully measured the dynam-
ics of Htt aggregation36. Unexpectedly, we found that the three candidate chemicals, 7H, #4028 (Angiotensin III) 
and L5387 (LH-RH 4–10 peptide fragment), remarkably increased the molecular weight of the final aggregation 
products (Fig. 5a). Moreover, during the initial phase of incubation, the process of aggregate formation was slow 
in the presence of the candidate chemicals but increased rapidly to form larger aggregates (Fig. 5a). On the basis 
of these findings, we conclude that these chemicals most likely interact with and change the dynamics of mutant 
Htt. The chemicals prolong the time in which mutant Htt exists as a monomer, shorten the time that GST-Htt 
exists as a small polymer that is most likely a protofibril, and increase the proportion of large polymers.
Taken together, these results support the hypothesis that the candidate chemicals interact with Htt polyQ pro-
tein either to promote aggregation or at the very least, to not prevent aggregation in a long time span.
www.nature.com/scientificreports/
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Figure 4. Expected common structure of candidate chemicals. (a) The structures of six chemicals that were 
effective for the Drosophila HD model are merged to extract the common features of the ternary structure. 
F1 is a donor/acceptor for hydrogen bonds and F2-4 are acceptors for hydrogen bonds. The positions for the 
hydrogen bond are common. The covalent bonds are colored red if the position is shared among five chemicals 
and are colored blue if the position is shared among the six chemicals. (b) The incorporation of 7H at the dip in 
the N-terminal region of Ku70 was visualized using Discovery Studio. (c) CD spectra of the three peptides, 7H, 
AngIII and LH-RH 4–10 partial peptide, are shown. In each panel, solid line, dashed line, and dotted line stand 
for 0, 10, and 20% HFIP, respectively. (d) Co-IP of Ku70 and mutant Htt with cerebral cortex samples from R6/2 
treated with 7H. The results obviously show decreased interaction between Ku70 and mutant Htt after treatment 
of 7H.
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Figure 5. Effect of candidate chemicals on Htt aggregation and human neurons from iPS cells of an 
HD patient. (a) The final three candidate chemicals, i.e., 7H, #4028 (Angiotensin III), and L5387 (LH-RH 
4-10 peptide fragment), affect the dynamic light scattering (DLS) measurements of GST-HttExon1-110Q 
aggregation in vitro. The three chemicals noticeably increased the molecular weight of the final aggregation 
products, whereas they slowed the initial phase of aggregate formation. (b) Two chemicals that were effective 
in the mouse HD model were re-examined using human neurons differentiated from the iPS cells of the HD 
patient. The decreased neurite length was reversed by treatment with 7H and Angiotensin III. Regarding the 
neurite length, we measured neurite lengths of two randomly selected neurons in a well, and the data of 10 wells 
were integrated. Mean + /− S.E. are shown in graph. ##p < 0.01 in Tukey’s HSD test. (C) Spine formation was 
evaluated using immunohistochemistry for PSD95. 7H and the Angiotensin III fragment reversed the decrease 
in the PSD95 spot number. PSD number per neurite was measured in two randomly selected neurons in a well 
and divided per neurite length (μ m). The values from multiple wells (n = 10) were integrated to mean + /− S.E. 
of each treatment in the graph. #p < 0.05 and ##p < 0.01 in Tukey’s HSD test. (d) Mutant protein aggregation was 
evaluated using immunohistochemistry for Htt. No effect was observed using the three chemicals. The number 
of neurons with Htt inclusion bodies was calculated in a randomly selected visual field of each well. and the 
mean + /− S.E. of 8 wells were calculated. (e) The decreased neurite length and branching point number of HD 
neurons were reversed by treatment with 7H and #4028 (Angiotensin III) at day 14 after neural differentiation. 
The branching number of neurite per a neuron was calculated for 3 or 4 randomly selected neurons in each well, 
and the mean + /− S.E. of 8 wells (30 neurons) were calculated. Statistical analyses used for (a–e) are shown in 
the figures.
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Validation using human neurons differentiated from HD iPS cells. Finally, to validate the ther-
apeutic effect on human neurons, the three candidate chemicals, Angiotensin III (#4028, RVYIHPF), 7H 
(HHHHHHH) and LH-RH 4–10 peptide fragment (L5387, SYGLRPG-NH2), were tested on human neurons 
derived from iPS cells of HD patients who had been established in the Coriell Institute (https://catalog.cori-
ell.org). Before usage, the characteristics of the iPS cells were re-examined. Neurons were differentiated from 
iPS cells according to a previously described protocol37, and these cells contained 80% β III-tubulin-positive 
neurons and 5% GFAP-positive glia. We also found that DARPP32-positive cells were hardly detected among 
β III-tubulin-positive neurons in our differentiation protocol, and most of them were TBR1-positive neurons cor-
responding to V–VI cortical layers (Supplementary Figure 6). Thus our object in this experiment was pan-neuron 
but not medium spiny striatal neurons. Confocal microscopy revealed a therapeutic effect of the screened chemi-
cals such that both the Angiotensin III (#4028, RVYIHPF) and 7H (HHHHHHH) improved the dendritic length 
at day 7 (Fig. 5b). Immunocytochemistry using PSD95 on day 14 revealed that the spine density was restored 
by the addition of 7H and the Angiotensin III (Fig. 5c). However, these chemicals did not reduce the number 
of inclusion body-positive neurons (Fig. 5d), as was expected from DLS results (Fig. 5a). Recovery of dendritic 
length and branching points was also confirmed at day 14 (Fig. 5e). Taken together, these results confirmed the 
therapeutic effect of final candidate chemicals on human neurons, which was independent of inclusion body 
formation.
Discussion
Hepta-histidine (7H), a seed for drug development against HD. In this study, we screened candidate 
drug seeds for the treatment of HD via multi-step screenings targeting the prevention of the abnormal interaction 
between Ku70 and mutant Htt. Consequently, we identified two definite and additional four promising seeds for 
drug development against HD. These chemicals shared common structural features and may interact with both 
Ku70 and mutant Htt. Unexpectedly, we found that 7H was more effective than numerous chemicals identified 
from a non-biased screening of chemical libraries in this study. Another interesting finding was that the final can-
didate chemicals did not inhibit but rather promoted the aggregation of mutant Htt. The latter result may provide 
additional insight about whether polyQ aggregates are toxic, protective or both.
We included 7H not only because it was proposed as a candidate on the basis of the in silico screening using 
Discovery Studio but also because it is a polar oligopeptide that might interact with a polyQ tract of Htt via multi-
ple hydrogen bonds of the polar zipper structure, as proposed by the Nobel Prize Laureate Max Perutz27. Histidine 
is one such polar amino acid that has a positively charged imidazole group, a positively charged amino group and 
a negatively changed carboxyl group, and amino acids possessing such polar groups generally contribute to the 
formation and maintenance of higher protein structures.
Oligopeptides are efficiently absorbed from the intestine to blood and are transported from the extracellular fluid 
into the cytoplasm by membrane transporters, such as ATP-binding cassette transporters (ABC transporters)38,39  
or proton-dependent oligopeptide transporters (PTR)40. Thus, the positive results in vivo with Drosophila and 
mouse models in this study could be explained by the efficient incorporation of oligopeptides into cells, which 
is advantageous for other low molecular weight chemicals when these oligopeptides progress to clinical trials.
Moreover, if 1,000 mg of 7H were uniformly diluted in a 70 kg human body, the final concentration is approx-
imately 12 μ M, which is within the range of concentrations that inhibit the abnormal interaction between Ku70 
and mutant Htt as found in this study. The concentration necessary to inhibit the interaction is one order or mag-
nitude lower (Supplementary Figure 3); thus, if the efficiency from the intestine to blood and that from the blood 
to brain is high, then an acceptable amount of hepta-histidine, such as 0.1–1.0 g/day (14–140 mg/kg/day), might 
be employed for a 70 kg person.
Another advantage of hepta-histidine is that oligo-histidine has been previously used as a tag of fusion 
proteins in a broad range of biological experiments for a long time, and the low toxicity has been previously 
established from these studies. Although we did not analyze the dose-effect or dose-toxicity relationships of 
hepta-histidine in this study, it is expected that a relatively high dose would be tolerable in model animals and 
human patients in a pre-clinical study and clinical trials. Importantly, the Roche license for the experimental 
usage of the hexa-histidine tag (EP0282042) expired in 1994.
Finally, to exclude the concern that 7H, Angiotensin III and LH-RH 4–10 peptide fragment might suppress 
the DNA damage repair function of Ku70 as a side effect through their interaction with Ku70, we analyzed the 
effect of these chemicals on DNA-PK activity with the method described previously24 and found that the three 
peptides did not suppress the DNA-PK activity at 50 and 100 μ M (Supplementary Figure 7). Instead, we unex-
pectedly found that 7H enhances DNA-PK activity (Supplementary Figure 7). Since we have already shown that 
7H dissociates abnormal interaction between mutant Htt and Ku70, the result is not contradictory to our conclu-
sion. The result also confirms that 7H and the other peptides have no side effect. It rather suggests that 7H has an 
additive function to enhance the therapeutic effect on HD.
Angiotensin III: another type of seed drug. Angiotensin III, RVYIHPF (Arg-Val-Tyr-Ile-His-Pro-Phe), 
is located at amino acids 35–41 in Angiotensinogen (NCBI reference Sequence: NP_000020.1). Angiotensinogen 
(435 amino acids) is expressed in the liver and activated in adipocytes and is then cleaved into Angiotensin I 
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) by a protease, renin, in the kidney. Furthermore, Angiotensin I is 
converted to Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) by the removal of two amino acids from the 
C-terminus by the angiotensin converting enzyme (ACE)41. The trimming of one or two amino acids produces 
Angiotensin III and Angiotensin IV (Val-Tyr-Ile-His-Pro-Phe), respectively. Furthermore, Angiotensin II has the 
strongest biological activity among the Angiotensins41. The vasopressor activity is also high for Angiotensin II but 
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not for Angiotensin I and is low for Angiotensin III (40% of the Angiotensin II activity) and Angiotensin IV42. In 
addition, the mineralocorticoid activity of Angiotensin III is similar to that of Angiotensin II42.
Thus, to proceed to clinical translation, it is necessary to decrease the mineralocorticoid activity of Angiotensin 
III. If the therapeutic activities of Angiotensin IV or other shorter peptides are confirmed against HD pathology 
in the same screenings, such derivatives of Angiotensin III will also be candidate drugs.
LH-RH peptide fragment and other chemicals are effective in a fly model. Although the ther-
apeutic effect of the LH-RH 4–10 peptide fragment was not confirmed in the HD mouse model, the effect was 
confirmed in an HD fly model. Thus, this peptide might still be viable as a candidate drug. In this regard, other 
chemicals that were effective in fly models should also be re-evaluated in the future.
Specifically, the Kemptide acetate salt (Leu-Arg-Arg-Ala-Ser-Leu-Gly) identified in this study is a strong can-
didate. It is a substrate of protein kinase A (PKA). Additionally, our finding suggests that the binding of mutant 
Htt to multiple proteins at this motif for PKA recognition impairs PKA signaling and subsequently results in 
impaired recognition and decreased memory in HD, as previously reported43.
Regarding the blood-brain barrier (BBB), the molecular weights of the chemicals selected from our third 
screening with Drosophila model were all greater than the cut-off value (400–600 Da) for transmembrane diffu-
sion proposed by Lipinski44, except FKL01282 (nordihydroguaiaretate, NDGA) (Fig. 3b). Thus, NDGA is another 
candidate drug seed for HD. Interestingly, another group also reported that NDGA was effective on R6/2 mice45. 
Taken together, the results strengthen the reliability of the chemicals selected from our integrated screening.
Although the molecular weights of the chemicals, including Kemptide acetate, are greater than 500 kDa, pep-
tides and proteins larger than 600 kDa are known to cross the BBB not only by transmembrane diffusion but also 
by peptide transporter or endocytosis46. Indeed, the 7,800 Da cytokine-induced neutrophil chemoattractant-1 
(CNC-1) is known to cross the BBB47.
Conclusion
We confirmed the therapeutic effect of 2 oligopeptides against HD pathology using in vitro and in vivo experi-
ments in a mouse model and with human iPS cells. However, 4 candidates still remain that have not been tested 
due to technical reasons or due to an effect at the borderline level when they were tested with the most severe HD 
mouse model. Thus, the six chemicals or their derivative chemicals could be candidate seeds for the development 
of therapeutic drugs against HD.
Methods
Construction of GST-Htt and His-Ku70 vectors. Human huntingtin exon 1 cDNA containing 
110 or 20 CAG repeats was subcloned into pGEX-3X (GE Healthcare) as previously described24. Mouse 
Ku70 cDNA was amplified from the RIKEN full-length enriched mouse cDNA library with 5′ -AAAGG 
ATCCATGTCAGAGTGGGAGTCCTA-3′ and 5′ -AAACTCGAGTGTTCTTCTCCAAGTGTCTGA-3′ primers 
and subcloned into the BamHI and XhoI sites of pET28(a) (Clontech).
Protein expression and purification. Plasmids for the GST-Htt and HisTag-Ku70 proteins were trans-
formed into E. coli Rosetta (DE3) (Novagen) competent cells. The transformed cells were cultured in shaker 
at 37 °C and 200 rpm. When the OD at 600 nm reached 0.3, IPTG (final concentration of 1.0 mM) was added 
and further incubated at 37 °C at 200 rpm for 2 hours. E. coli cells were collected by centrifugation and lysed in 
20 ml of PBS containing 0.1% Tween 20, 0.1% Lysozyme (Sigma), and 1/500 Protease Inhibitor Cocktail III–
EDTA-free (Calbiochem) for the GST-Htt protein and in 20 ml of PBS containing 10 mM imidazole, 1% Triton 
X-100, and 1/500 Protease Inhibitor Cocktail III - EDTA-free (pH 8.0) for the HisTag-Ku70 protein. The sus-
pension was sonicated seven times for 15 sec at 1 min intervals using output level 6 (Ultrasonic homogenizer: 
UH-50, SMT Company) and centrifuged at 12,000 × g for 20 min at 4 °C. The supernatant was mixed with 4 ml 
of 50% Glutathione Sepharose 4B (GE Healthcare) for GST-Htt protein or with 50% Ni-NTA Agarose (Qiagen) 
for HisTag-Ku70 protein, equilibrated with PBS containing 0.1% Tween 20, and rotated slowly for 3 hours at 4 °C. 
The GST-Htt suspension was applied to a Glutathione Sepharose 4B column at 4 °C, washed with 32 ml of PBS 
containing 0.1% Tween 20 (pH 8.0), and eluted four times with 4 ml of 10 mM glutathione in PBS containing 0.1% 
Tween 20 at 4 °C by gravity flow. The HisTag-Ku70 suspension was applied to a Ni-NTA Agarose column at 4 °C, 
washed with 32 ml of 20 mM imidazole in PBS containing 1% Triton X-100 (pH 8.0), and eluted four times with 
4 ml of 10 mM glutathione in 250 mM imidazole in PBS containing 1% Triton X-100 (pH 8.0) at 4 °C by gravity 
flow. Each fraction was dialyzed and stirred with 2 L of PBS containing 0.01% Tween 20 for 12 hours at 4 °C twice. 
The purified Ku70 protein was labeled with fluorescent dye using a Protein Labeling Kit (488 nm and 633 nm) 
(Olympus).
Single molecule fluorescence spectroscopy. Fluorescence intensity distribution analysis polarization 
(FIDA–PO) and fluorescence correlation spectroscopy (FCS) analyses were performed using an MF20 (Olympus 
Corporation), which detects the single-molecule fluorescence in 40 μ l/well samples of 384-well glass-bottom 
plates using a confocal laser microscope at room temperature. The samples contained 5 nM fluorescent Ku70 
protein in PBS containing 0.01% Tween 20 and 1% DMSO. The data of FIDA-PO and FCS were acquired from 
10 times of experiments per well and the results from two wells were analyzed using the Bonferroni/Dunn test. 
In total, 18,500 chemicals from the Chemical Biology Screening Center of Tokyo Medical and Dental University 
were screened.
In silico screening. All simulations were performed using Discovery Studio 2.5 (Dassault Systems BIOVIA 
Cooperation, San Diego) with a database of commercially available compounds, Chemical Available Purchase 
(CAP) 2006 (Dassault Systems BIOVIA Cooperation, San Diego). The structures of poly(amino acids) (fewer 
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than ten residues) were generated using the command ‘Build and Edit Protein’ and were used for the binding 
simulation in Discovery Studio 3.0.
A crystal structure of the Ku heterodimer bound to DNA (PDB ID: 1JEY) was downloaded from the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB), and the crystal structure of iso-
lated Ku70 was imported from the complex (1JEY). The “prepare protein protocol” in Discovery Studio 3.0 was 
used to prepare the Ku70 structure for further processing. The protocol standardizes atoms names, applies the 
CHARMm (Chemistry at HARvard Macromolecular Mechanics) force field, and protonates amino acid residues 
except the inserts of missing loops. During preparation, default parameters were used, except ‘Build Loops:False’. 
The prepared Ku70 was used to define the binding site through the ‘Find Sites from Receptor Cavities’ option on 
the ‘Define and Edit Binding Site’ tool bar. Here, default parameters were used except ‘Site Opening: from 5.0 Å 
to 10.0 Å ′ . Chemicals were treated using the built-in ligand preparation wizard of Discovery Studio 2.5. Default 
parameters were used except ‘General Tautomers: False, General isomer: False, Fix Bad Valences: False’. In total, 
3,010,121 chemicals were collected from CAP 2006 and examined using LibDock, a high-throughput algorithm 
for docking ligands into the binding site on the receptor48 to guide docking.
Fly screening. All flies were raised on corn meal medium (9.2% corn meal, 3.85% yeast, 3.8% sucrose, 1.05% 
potassium tartrate, 0.09% calcium chloride, 7.6% glucose, 2.416% nipagin, and 1% agar) and maintained at 25 °C 
and 60% ± 10% humidity under a 12:12-h light-dark cycle unless otherwise noted.
UAS-Htt103Q and OK6-Gal449 transgenic flies were crossed, and the F1 virgin female flies were subjected to 
lifespan screening. The chemicals or peptides for screening were dissolved in D.W. or ethanol at 5 mM and homo-
geneously mixed with 9 times the volume of corn meal medium to obtain a final concentration of 500 μ M. For the 
control medium, only D.W. or ethanol was added. Twenty virgin female flies were maintained per vial and trans-
ferred to new vials with fresh medium every 2–3 days. The number of dead flies was quantified every 2–3 days.
Administration of chemical compounds to R6/2 and mutant Htt-KI mice. Male R6/2 mice and 
their background mice (CBA/J) were maintained at 22 °C on a 12 h light/dark cycle (light on at 8:00 am and off 
at 8:00 pm) and had free access to water and standard chow pellets (CLEA Rodent Diet CE-2, CLEA Japan, Inc., 
Tokyo, Japan) prior to the start of the experiments. The mice received an intraperitoneal injection of a chemical 
compound dissolved in PBS at 50 μ g/g body weight once a week from 3 weeks of age. Survival ratios were ana-
lyzed using the log-rank test. Mutant human Htt gene-KI mice34 (HdhQ111 mice) were generous gift from Prof. 
Marcy MacDonald (Harvard Medical School). They were maintained and similarly and received an intraperito-
neal injection of 7H dissolved in PBS at 50 μ g/g body weight everyday for one week from 54 weeks of age.
Western blotting analysis. The cerebral cortical tissues of 12-week-old mice were washed three times 
with ice-cold PBS and dissolved in lysis buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 2.5% (v/v) 
2-mercaptoethanol, 5% (v/v) glycerol, and 0.0025% (w/v) bromophenol blue. The protein concentration was 
quantified using the BCA method (Pierce BCA Protein Assay Kit; Thermo Scientific, IL, USA). These samples 
were separated by SDS-PAGE, transferred to an Immobilon-P polyvinylidene difluoride membrane (Millipore, 
MA, USA) through a semi-dry method, blocked by 5% milk in TBST (10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 
and 0.05% Tween 20). Primary and secondary antibodies were diluted in TBST with 0.5% skim milk or Can 
Get Signal solution (Toyobo, Osaka, Japan) as follows: mouse anti-γ H2AX, 1:1,000 (Ser139, #05-636, Millipore, 
MA, USA); rabbit anti-53BP1, 1:30,000 (NB100–304, Novus Biologicals, CO, USA); rabbit anti-Htt (CAG53b), 
1:100,000 (a generous gift from Prof. Erich Wanker, Max Delbrück Center for Molecular Medicine, Berlin, 
Germany); anti-GAPDH, 1:1,000–10,000 (MAB374, Millipore; HRP-linked anti-rabbit IgG, 1:3,000 (NA934, GE 
Healthcare, Little Chalfont, United Kingdom); and HRP-linked anti-mouse IgG, 1:3,000 (NA931, GE Healthcare, 
Little Chalfont, United Kingdom). Primary and secondary antibodies were incubated overnight at 4 °C and 
for one hour at room temperature, respectively. ECL Prime Western Blotting Detection Reagent (RPN2232, 
GE Healthcare, Little Chalfont, United Kingdom) and luminescent image analyzer (ImageQuant LAS 500, GE 
Healthcare, Little Chalfont, United Kingdom) were used to detect proteins.
Mouse motor function. Mice were maintained at 22 °C on a 12 h light/dark cycle (lights on at 8:00 am and 
off at 8:00 pm) and had free access to water and standard chow pellets (CLEA Rodent Diet CE-2, CLEA Japan, 
Inc.). Survival curves were analyzed using the log-rank test.
For the rotarod test, the mice were placed on a rotating rod (shaft diameter: 3.2 cm, lane width: 5.7 cm, fall 
height: 16.5 cm; Five Station Rotarod Standalone for Mouse, ENV-577M, MED Associates Inc., USA), and the 
speed of rotation was increased linearly from 0 to 35 rpm in 300 sec and maintained at 35 rpm for an additional 
60 sec (for 4- to 12-week-old mice). The mice were examined in three trials performed on three consecutive days. 
The mean latency to fall off the rotarod in the three trials was recorded.
Mouse immunohistochemistry. Immunohistochemical analysis was performed using mouse brains fixed 
in 4% paraformaldehyde for 12 to 16 hours. Mouse paraffin sections were deparaffinized in xylene followed by 
rehydration in ethanol diluted in serial dilutions and microwaved in 0.01 M citrate buffer, pH 6.0, at 120 °C for 
15 min. The brain area was delimited using a DAKO pen (S2002, Agilent’s Dako, Glostrup, Denmark) and incu-
bated overnight at 4 °C with primary antibodies. The next day, mouse brain sections were washed and incubated 
with secondary antibodies at room temperature for 1 hour. The antibodies and respective dilutions used included 
anti-γ H2AX antibody, 1:200 (Ser139, #05-636, Millipore, MA, USA); rabbit anti-53BP1, 1:5000 (NB100-304, 
Novus Biologicals, CO, USA); anti-DARPP-32, 1:200 (Cell Signaling Technology, #2306, MA, USA); anti-Htt, 
1:100 (EM48, #MAB5374, Millipore, MA, USA); anti-rabbit IgG Cy3, 1:1000 (711-165-152, Jackson Laboratory, 
Bar Harbor, ME, USA); anti-mouse IgG Alexa488, 1:1000 (A21202, Molecular Probes, OR, USA); anti-mouse 
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IgG Cy3, 1:1000 (715-165-150, Jackson Laboratory, ME, USA); and anti-rabbit IgG Alexa488, 1:1000 (A21206, 
Molecular Probes, OR, USA).
DNA-dependent protein kinase activity assay. The experiment was performed as described previ-
ously24. In brief, DNA-PK activity was measured using SignaTECT DNA-dependent Protein Kinase Assay System 
(Promega, #V7870, WI, USA) and ADP-Glo Kinase Assay (Promega, #V9101, WI, USA). Nuclear extracts of 
HEK293 cells were obtained using Nuclear Extract kit (Active Motif, #40010, CA, USA). Briefly, three peptides 
(7H, AngIII, LH-RH 4–10) were independently added into the reaction buffer mixture (DNA-PK activation 
buffer, DNA-PK 5xReaction buffer, DNA-PK biotinylated peptide substrate, BSA (66 μ g/ml) and ATP (16.5 μ M)), 
and after 10 minutes incubation at 30 °C, nuclear extracts were added. Kinase reaction was terminated by addition 
of ADP-Glo reagent. After ATP was removed, ADP remained was converted again to ATP by Detection Reagent, 
and the synthetized ATP was detected by luciferase reaction.
Pull-down assay. Nuclear extracts of HeLa cell were obtained in accordance with our previous experimental 
protocol24. His-Ku70 or His-Tau (10 μ g) were mixed with nuclear extracts and incubated for 12 hours at 4 °C, 
added with 50% Ni-NTA agarose (100 μ L, Qiagen, Hilden, Germany), rotated for 3 hours at 4 °C, centrifuged 
at 500 g and washed with PBS (three times), and solubilized with sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% 
(w/v) SDS, 2.5% (v/v) 2-mercaptoethanol, 5% (v/v) glycerol, and 0.0025% (w/v) bromophenol blue). The sam-
ples were subjected to Western blotting following the method described above. Primary and secondary anti-
bodies were used as follows: mouse anti-His antibody (diluted at 1:3000, BioDynamics Laboratory Inc., #F008, 
Tokyo, Japan), anti-rabbit anti-ku80 (1:1000; H300; Santa Cruz Biotechnology, Inc. Texas, USA), anti-mouse 
IgG HRP-conjugated (1:3000, NA931, GE Healthcare, Little Chalfont, United Kingdom). Primary and secondary 
antibodies were incubated overnight at 4 °C and for one hour at room temperature, respectively.
Common structure expectation. The six compounds, including Kemptide acetate salt (CID; 100074), 
Angiotensin III (CID; 71464372), Nordihydroguaiaretate (CID; 4534), Luteinizing hormone-releasing hormone 
fragment (CID; 4224599), 7H (hepta-histidine), and 7Q (hepta-glutamine), were multiply aligned using the flex-
ible alignment method of Molecular Operating Environment (MOE) (2013.08; Chemical Computing Group Inc., 
Montreal, QC, Canada) with the default parameter setting. We employed the top scoring alignment among 100 
candidates generated by the method to search for potential pharmacophores using the Pharmacophore Consensus 
application of MOE. In this study, the pharmacophore was defined as an atom that was common to at least five 
compounds in the alignment. Consequently, four pharmacophores were identified. One of the pharmacophores 
was a hydrogen bond acceptor (F1), and three of the pharmacophores were hydrogen bond donors (F2–F4).
CD spectra. To investigate the secondary structures of the 3 peptides, 7H, AngIII, and LH-RH 4–10 frag-
ment, their CD spectra were taken at 25 °C on a Jasco J-720 spectropolarimeter using an optical cuvette with a 
pathlength of 1.00 mm for measurements in the peptide region (200–250 nm). The concentrations of the peptides 
were 74–106 μ M in PBS, which were estimated spectrophotometrically by applying the typical formula50. The 
concentrations of HFIP were set at 10 and 20% by adding appropriate amount of HFIP into the peptide solutions.
Dynamic light scattering analysis. Dynamic light scattering (DLS) was performed on a Zetasizer μ V 
instrument (Malvern Instruments Ltd.) to monitor the aggregation time course of huntingtin in the presence and 
absence of the drugs. Ten micromolar protein was incubated with 500 μ M of each of the three drugs at 25 °C in 
PBS buffer for 6 days, and its DLS signal was recorded every several hours. The term “Z-average size” was applied 
as an index of aggregation (ISO-22412:2008). Each measurement was repeated four times, and the average of the 
four measurements was calculated.
Culture of iPS cells. 201B7 was derived from RIKEN BRC (https://ja.brc.riken.jp). CS92iHD-57n9 iPS cells 
of HD patients had been established in the Coriell Institute (https://catalog.coriell.org). CAG repeat number was 
57.
Karyotyping of iPS cells. Standard G-banding analysis of iPS cell lines (201B7 and CS92iHD-57n9) was 
performed to rule out the possibility of abnormal karyotypes that can occur during the generation of iPSCs.
In vitro differentiation of iPS cells. Neural differentiation of iPS cells was performed as previously 
described51 with minor modifications. Briefly, the iPS cells were plated on a 10-cm dish and maintained for longer 
than 5 days with 3 μ M SB431542, 3 μ M CHIR99021 and 3 μ M deosomorphine. Next, iPS cells were detached 
from a feeder layer and dissociated into single cells, which were cultured in 2 × B27 supplemented KBM medium 
(KHOJIN BIO, Saitama Japan) with 20 ng/ml bFGF, 10 ng/ml hLIF, 10 μ M Y27632, 3 μ M CHIR99021 and 2 μ M 
SB431542 in a suspension culture condition in a 10-cm cell-repellent dish to form neurospheres. Neurospheres 
were passaged 2 times and differentiated into neural cells using an adhesion culture method (DMEM/F12 supple-
mented with B27 and Glutamax). Neurons were allowed to adhere to poly-L-ornithine- and poly-L-Lysine-coated 
coverslips for 14–21 days.
Immunostaining of iPS and differentiated cells. Cells were fixed with PBS containing 4% paraformal-
dehyde for 15 min on ice and incubated with primary antibodies against the following proteins: SSEA1 (1:1000, 
Abcam, ab16285), Nanog (1:200, RCAB0004PF ReproCELL, Yokohama, Japan), β III tubulin (1:1000, T8660 
Sigma Chemical Co., MO, USA), α SMA (1:150, M085101 Dako, Glostrup, Denmark), SOX17 (1:500, ab84990 
Abcam, Cambridge, UK), DARPP-32 (1:200, #2302S, Cell signaling, MA, USA), Cux1 (1:200, sc-13024, Santa 
Cruz Biotechnology, Inc., TX, USA) and TBR1 (1:200, ab31940, Abcam, Cambridge, UK). The cells were then 
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washed with PBS and incubated with an Alexa Fluor 488-, Alexa Fluor 555-, or Alexa Fluor 647-conjugated sec-
ondary antibody (1:500, Invitrogen, CA, USA).
Statistics. For lifespan assays of fly and mouse models, Log-rank test was used. For the other biological anal-
yses, the data were considered to follow a normal distribution and are represented as the mean ± standard error. 
Student’s t-test was applied for two group comparisons (a chemical-treated group v.s. PBS group). For multiple 
group comparisons, Tukey’s HSD test or Dunnett’s comparison were applied. The significance level was set at 1% 
or 5%.
The power of statistical test was determined as the probability that the null hypothesis was correctly rejected. 
The power was estimated using sample size, significance level and effect size (ES). Effect size was calculated using 
Cohen’s d value52.
Ethics. This study was performed in strict accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. It was approved by the Committees on 
Gene Recombination Experiments, Human Ethics, and Animal Experiments of the Tokyo Medical and Dental 
University (Numbers: 2010-215C14, 2014-5-4 and 0160328C, respectively).
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